NCT05873907View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

64

Participants

Timeline

Start Date

October 19, 2015

Primary Completion Date

June 16, 2017

Study Completion Date

July 28, 2017

Conditions

Chronic Graft-versus-host Disease (cGVHD)

Interventions

DRUG

AMG 592

Administered as SC injection

OTHER

Placebo

Administered as SC injection

Trial Locations (1)

33180

Research Site, Aventura

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY